EPC-004 / Elpis Biopharma - LARVOL DELTA

Discovery and development of fully human TACI/BCMA bispecific armored CAR for the treatment of relapsed/refractory multiple myeloma (AACR 2023) - "EPC-004, engineered with multi-modules and multi-mechanisms is a promising candidate which enhances anti-tumor activity, prevents target escape, reduces immunosuppression within the bone marrow tumor microenvironment. These novel mechanisms could potentially translate EPC-004 into durable clinical efficacy in treating R/R multiple myeloma."

Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Oncology • IL2